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Abstract
Background: a-Dystroglycan is a negatively charged glycoprotein that covers the apical and basolateral membrane of the
podocyte. Its transmembrane binding to the cytoskeleton is regulated via tyrosine phosphorylation (pY892) of b-
dystroglycan. At the basolateral side a-dystroglycan binds the glomerular basement membrane. At the apical membrane, it
plays a role in the maintenance of the filtration slit. In this study, we evaluated whether ligation of a-dystroglycan with
specific antibodies or natural ligands induces intracellular signaling, and whether there is an effect on podocyte
architecture.
Methodology/Principal Findings: Conditionally immortalized podocytes were exposed in vitro to antibodies to a-
dystroglycan, and to fibronectin, biglycan, laminin and agrin. Intracellular calcium fluxes, phosphorylation of b-dystroglycan
and podocyte architecture were studied. Antibodies to a-dystroglycan could specifically induce calcium signaling.
Fibronectin also induced calcium signaling, and led to dephosphorylation of pY892 in b-dystroglycan. Ligation of a-
dystroglycan resulted in an altered actin architecture, a decreased number of podocyte pedicles and a more flattened
appearance of the podocyte.
Conclusions/Significance: We conclude that ligation of a-dystroglycan on podocytes induces intracellular calcium
signaling, which leads to an altered cytoskeleton architecture akin to the situation of foot process effacement. In particular
the ability of fibronectin to induce intracellular signaling events is of interest, since the expression and excretion of this
protein is upregulated in several proteinuric diseases. Therefore, fibronectin-induced signaling via dystroglycan may be a
novel mechanism for foot process effacement in proteinuric diseases.
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Introduction
Podocytes are highly specialized glomerular visceral epithelial
cells that cover the outside of the glomerular basement membrane
[1]. Podocytes together with the glomerular basement membrane
and the glomerular endothelium constitute the size and charge
selective filter of the glomerulus. The podocyte cell body forms
primary and secondary extensions, which form foot processes that
interdigitate with those of neighboring podocytes and that are
attached to each other by the slit diaphragm. In many glomerular
diseases with proteinuria, podocyte foot processes are effaced, as
their extensions are lost.
Dystroglycan was identified as a component of the dystrophin
glycoprotein complex, which is involved in muscular dystrophies
[2,3]. Thereafter, dystroglycan was described as a component in
epithelial cells [4,5], and we have shown that dystroglycan is
expressed by podocytes, both at the basolateral and the apical cell
membrane [6,7]. The dystroglycan encoding gene DAG1 was first
cloned and sequenced in 1992. Dystroglycan is post-translationally
cleaved into the extracellular a subunit and the integral membrane
b subunit, which non-covalently interact [2]. Dystroglycan provides
a link betweenthe extracellular matrixlikethe glomerular basement
membrane to the actin cytoskeleton of the podocyte. a- Dystrogly-
can binds to laminin G modules that are present in laminin and
agrin, whereas b-dystroglycan is connected to the actin cytoskeleton
via dystrophin or its ubiquitous homologue utrophin in the kidney
[6,8,9]. a-Dystroglycan undergoes massive O-mannosyl glycosila-
tionwith terminal sialicacids,whichserveby virtue of theirnegative
charge as an anti-adhesion layer on the apical podocyte membrane,
analogous to podocalyxin, a sialic acid-rich glycoprotein that also
covers the apical cell membrane of the podocyte [7]. The
glycosilation of a-dystroglycan is necessary for its binding to laminin
G modules [8]. We have shown previously that deglycosilation of a-
dystroglycan by reactive oxygen species results in a loss of bindingto
agrin and laminin [10].
The small leucine-rich repeat at the C-terminal tail of a-
dystroglycan has been shown to bind to chondroitin sulfate A and/
or C on biglycan [11]. Biglycan is a small leucine-rich
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chains. It has been shown to be predominantly localized in the
tubular interstitium and intrarenal arteries. Minimal expression of
biglycan in the mesangial matrix has been described for normal
human kidney and various glomerular diseases [12–16]. TGF-b-
mediated mesangial upregulation of biglycan has been described
in Thy-1 mediated membranoproliferative glomerulonephritis in
the rat [17]. TGF-b induces fibrosis and as a consequence it is
especially co-localized with collagen type I in fibrosis [13].The
assembly of chondroitin sulfate side chains decreases after
exposure to puromycin-aminonucleoside and dexamethasone
[18,19]. Biglycan is not detectable in the urine of patients with
glomerular diseases [15].
It was recently shown that the C-terminal domain of muscle a-
dystroglycan can also bind to fibronectin and fibrinogen [20].
Fibronectin is a 500 kDa protein that consists of two similar
250 kDa subunits linked via a disulfide bond. By post-translational
processing plasma and tissue isoforms are formed. An increased
expression of both plasma and tissue fibronectin has been
documented in various glomerular diseases like diabetic nephrop-
athy, puromycin-aminonucleoside and adriamycin nephrosis [21–
24]. Furthermore, urinary excretion of fibronectin has been shown
to correlate with proteinuria in IgA-nephropathy, membranous
glomerulopathy, and diabetic nephropathy and with glomerulo-
sclerosis in lupus nephritis and chronic glomerulonephritis [25–27].
The extracellular N-terminal domain of b-dystroglycan interacts
with a-dystroglycan, whereas the intracellular C-terminal domain
interacts with utrophin [28–30]. In particular, a PPxY motif
including a tyrosine residue at position 892 in b-dystroglycan in
the C-terminal domain is necessary for interaction with WW
domains in utrophin [28–30]. WW domains are 30–40 amino acid
motifs containing two conserved tryptophan residues, that bind to
proline-rich sequences [31]. The interaction of b-dystroglycan
with dystrophin/utrophin is stabilized by a helix-turn-helix motif,
i.e. EF hand, close to the PPxY motif in dystrophin/utrophin
[29,32]. Furthermore, dephosphorylation of Y892 (pY892) in b-
dystroglycan enables binding to utrophin/dystrophin [30,33].
Phosphorylation of b-dystroglycan enhances recruitment of SH2/
SH3 domain containing proteins like c-Src, Fyn, Csk, NCK, SHC
and Grb-2, which all are involved in signaling events [34,35]. This
suggests a role for dystroglycan in signaling.
In this study, we investigated whether ligation of a-dystroglycan
by monoclonal antibodies against a-dystroglycan and natural
ligands for a-dystroglycan, such as laminin, agrin, biglycan and
fibronectin, leads to intracellular signaling as assessed by
measuring calcium fluxes and to changes in the phosphorylation
status of b-dystroglycan at position 892 (Y892). In addition, we
investigated whether a-dystroglycan ligation had an impact on
actin cytoskeleton architecture and podocyte morphology.
Results
The binding of cultured mouse podocytes to EHS laminin,
agrin, collagen A and Matrigel coated plates was quantified with
the hexosaminidase assay. Podocytes were pre-incubated with a-
dystroglycan specific antibodies, IIH6 or VIA4.1, directed to
carbohydrate epitopes on a-dystroglycan, prior to seeding on the
coatings. It is known that monoclonal antibody IIH6 inhibits the
binding of a-dystroglycan to laminin G modules, whereas
monoclonal antibody VIA 4.1 does not [4,36]. Indeed, the
number of podocytes binding to laminin decreased after pre-
incubation with IIH6, but remained unaltered after pre-incubation
with VIA4.1 (Figure 1A). Pre-incubation with isotype controls for
either of the a-dystroglycan antibodies (TEPC and MOPC
respectively) did not affect the binding. As expected, similar
results were obtained with agrin as coated ligand (data not shown).
However, the binding of podocytes to collagen A, which is
comprised of type I collagen that does not contain laminin G
modules, was unaltered by the addition of either of the two a-
dystroglycan specific antibodies (Figure 1B). Furthermore, the
binding of podocytes to Matrigel which is considered as a
surrogate basement membrane preparation containing a mixture
of several extracellular matrix molecules, could not be prevented
by MoAb IIH6 (data not shown). Therefore, monoclonal antibody
IIH6 specifically inhibits the binding of mouse podocytes to
laminin EHS and agrin, indicating an important role for a-
dystroglycan for the binding of podocytes to laminin G modules
containing proteins such as laminin and agrin in the glomerular
basement membrane.
Next, we analyzed whether a-dystroglycan on mouse podocytes
could mediate outside-in signaling. The ability of monoclonal
antibodies IIH6 and VIA 4.1 and their respective isotype controls
to induce calcium fluxes was assessed by the fura 2 method, which
measures the cytosolic calcium concentration. Both monoclonal
antibodies could specifically induce calcium signaling after ligation
of a-dystroglycan, whereas the isotype controls did not (Figure 2A,
Figure 1. Inhibition of podocyte binding to laminin by anti a-dystroglycan monoclonal antibodies IIH6 and VIA 4.1. Podocytes were
seeded on laminin (A) or collagen A coatings (B) after pre-incubation with either monoclonal antibody IIH6 using TEPC as an isotype control, or with
VIA 4.1 using MOPC 21 as an isotype control. Monoclonal antibody IIH6 specifically inhibits podocyte binding to laminin, but not to collagen A.
doi:10.1371/journal.pone.0005979.g001
Ligation of a-Dystroglycan
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5979Figure 2. Calcium fluxes in cultured mouse podocytes after ligation of a-dystroglycan. Mouse podocytes were differentiated on collagen
A coatings for 2 weeks. Intracellular calcium concentrations were monitored by the fura-2 method, with and without extracellular calcium. Both a-
dystroglycan specific monoclonal antibodies induced calcium fluxes, most likely from intracellular stores. Isotype controls were negative (A, B). The
laminin G modules-containing proteins agrin and laminin were unable to induce a calcium influx in podocytes (C, D). From the natural ligands of a-
dystroglycan tested, fibronectin induced the most pronounced calcium influx. Note that blocking of potential integrin binding sites with a RGD
peptide did not influence the fibronectin effect (E). The proteoglycan biglycan induced a modest calcium influx (F).
doi:10.1371/journal.pone.0005979.g002
Ligation of a-Dystroglycan
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the presence or absence of extracellular calcium, indicating that
the cytosolic calcium influx was derived from the intracellular
calcium stores. Although these experiments indicate that ligation
of a-dystroglycan mobilizes intracellular calcium stores, this
induction by specific antibodies is however, not a physiological
event. Therefore, the ability of natural ligands of a-dystroglycan to
induce a similar rise in cytosolic calcium was investigated. Both
laminin and agrin, which both can bind to glomerular a-
dystroglycan [10], were not able to induce a rise in cytosolic
calcium (Figure 2C, D). Biglycan induced a modest calcium influx
(Figure 2F). Since the interaction of biglycan with muscle a-
dystroglycan depends on the chondroitin sulfate side chains of
biglycan [11], we also tested the effect of adding chondroitin
sulfate A, B and C, and heparan sulfate. However, both
chondroitin sulfate preparations as well as heparan sulfate did
not induce calcium mobilization in the cytosol (data not shown).
Since fibronectin is a known ligand of muscle a-dystroglycan, and
a protein which is involved in several glomerular diseases [21–27],
we evaluated the effect of fibronectin on calcium fluxes. Since we
could not rule out that RGD motives in fibronectin could induce
signaling via a3b1integrin, these RGD fibronectin receptor
recognition sequences in integrins were blocked by pre-incubation
with RGD peptide. We included RGD blocking, although
a3b1integrins are mainly expressed at the basal and not at the
apical side of podocytes. Addition of RGD peptide did not result in
calcium fluxes. Fibronectin, after blocking of a3b1integrin with
RGD peptides, induced the strongest cytosolic calcium influx of all
4 endogenous ligands of a-dystroglycan tested (Figure 2E). This
finding indicates that fibronectin can induce calcium fluxes in
podocytes, via other molecules than integrins. To further
investigate whether the dystroglycan complex is involved in
fibronectin-induced calcium fluxes in podocytes, its effect on the
phosphorylation state of Y892 in b-dystroglycan was investigated.
It appeared that stimulation of podocytes by fibronectin
(concomitantly with blocking with RGD peptide) led to a decrease
in phosphorylation of Y892, while the total amount of b-
dystroglycan was unaltered (Figure 3). This latter finding suggests
that a-dystroglycan is involved in fibronectin-induced calcium
influxes in podocytes. We have also studied the expression level of
pY892 in renal sections of control rats and rats with adriamycin
nephropathy, with normal and effaced podocytes, respectively. We
applied several antigen retrieval techniques, and an epitope
preservation approach by inclusion of phosphatase inhibitors.
However, despite an additional signal amplification, the detectable
expression levels of pY892 in both control and adriamycin rats
were extremely low and, therefore, not conclusive (data not
shown), which seems in contrast to our clear findings with Western
blot analysis (Figure 3). However, a similar discrepancy between
immunofluorescence and Western blot analysis has been observed
on skeletal muscle by others [37]. It has been described that
differentiation of conditionally immortalized podocytes induces
process (filopodia) formation [38]. In figure 4 we show the effect of
the anti-a-dystroglycan monoclonal antibodies and fibronectin on
the morphology of podocytes and actin cytoskeleton. All ligands
induced a retraction of filopodia and a reorganization of the
cytoskeleton. Statistical analysis of these effects revealed a
significant effect for the anti-a-dystroglycan monoclonals IIH6
and VIA 4.1, but only a trend for fibronectin (Table 1). However,
in several fibronectin-stimulated cells retraction of filopodia was
clearly visible as shown in the lower panels of figure 4. This
reorganization of the actin cytoskeleton may be a situation
reminiscent of foot process effacement. These data suggest that
fibronectin-induced signaling events, mediated by the dystroglycan
complex leads to an altered podocyte architecture.
Discussion
a-Dystroglycan is a negatively charged glycoprotein, which
covers the apical and basolateral membrane of the podocyte. At
the basolateral side a-dystroglycan binds laminin G modules in
agrin and laminin. The a3b1integrin is also expressed at the
basolateral side of podocytes, where it extracellulary binds to
laminin, fibronectin and collagen. In this study we investigated the
importance of a-dystroglycan for the binding of podocytes to
laminin, agrin and several other extracellular matrix molecules
with a new binding assay. Binding of monoclonal antibody IIH6
but not monoclonal antibody VIA4.1 inhibited the binding of
podocytes to laminin and agrin. Our findings with podocytes are
similar to the data for the binding of Schwannoma cells to laminin
as previously described [36]. This is also underlined by the
observation that monoclonal antibody VIA 4.1 did not inhibit the
binding/growth of podocytes to collagen nor to laminin and agrin,
since the carbohydrates recognized by VIA4.1 are not involved in
the binding to laminin G moieties [4,36]. However, no
impairment of binding of podocytes to collagen type I coated
plates was observed after incubation with monoclonal antibody
IIH6. Furthermore, binding of podocytes to Matrigel-coated plates
also could not be inhibited by IIH6, which not unexpectedly
suggests that podocytes also can bind to additional molecules
without laminin G modules. As over 50% of the binding of
podocytes to laminin was lost by the addition of monoclonal
antibody IIH6, it can be concluded that for binding to laminin a-
dystroglycan on podocytes is of equal or even greater importance
than a3b1integrins. Therefore, our in vitro findings suggest that a-
Figure 3. Fibronectin stimulation of cultured mouse podocytes
leads to a decrease of pY892 on b-dystroglycan. Cultured mouse
podocytes were incubated for 3 minutes with fibronectin after which a
decrease of pY892 was found in Western blot analysis of whole
podocyte cell lysates (right panel), whereas the total amount of b-
dystroglycan was not affected (left panel). Total b-dystroglycan was
probed with NCL-BDG and pY892 was probed with anti-pY892.
doi:10.1371/journal.pone.0005979.g003
Ligation of a-Dystroglycan
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anchor to the glomerular basement membrane.
At the apical domain of the podocyte the assumed function of
the dystroglycan complex is maintenance of the filtration slit by its
negative charge [7]. In this study, we investigated whether
dystroglycan plays a role in outside-inside signaling events. Indeed,
we observed a specific cytosolic calcium influx in cultured mouse
podocytes after ligation of a-dystroglycan by two different anti a-
Figure 4. Ligation of a-dystroglycan results in a loss of pedicles in cultured mouse podocytes. Differentiated podocytes on collagen
coatings were incubated with either monoclonal antibodies IIH6 or VIA 4.1, their respective isotype controls (TEPC or MOPC) or fibronectin. The
podocyte pedicles (arrow) are probed with antibodies against Mena (green, which also localizes along stress fibers and in focal contacts at the tips of
stress fibers [58,65]). The pedicles were lost after 6 hours of incubation with the antibodies. As these pedicles may be the in vitro manifestation of foot
processes, their retraction may imply foot process effacement. Percentage of podocytes with smooth surfaces were counted, which yielded for IIH6
60% versus TEPC 30% (x
2=20.8, p,0.001), for VIA4.1 51% versus MOPC 28% (x
2=9.01, p,0.01) and fibronectin 38% versus control 30% (x
2=1.3,
p=0.25). (Red=phalloidin (actin); blue=DAPI (DNA)).
doi:10.1371/journal.pone.0005979.g004
Ligation of a-Dystroglycan
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concentration comes mainly from the intracellular calcium stores,
since it was not dependent on the extracellular calcium
concentration. This increase in cytosolic calcium is presumably
mediated via inositol-1,4,5 tri-phosphate in the endoplasmatic
reticulum [39].
Since induction of calcium fluxes by these anti a-dystroglycan
specific antibodies is not a physiological event, we were interested
in the effects of natural ligands of dystroglycan like, laminin, agrin,
biglycan and fibronectin. From these ligands fibronectin induced
the most pronounced signal, biglycan induced only a weak
increase in cytosolic calcium, while agrin and laminin were not
able to induce such an effect. This difference may be related to the
fact that the function of a-dystroglycan on the basal side of the
podocyte is different from the function at the apical side.
Furthermore, clustering of a-dystroglycan can be induced by the
antibodies, fibronectin and biglycan, as they may all serve as
bivalent ligands [20]. In contrast, agrin and laminin probably
serve as monovalent ligands. Tandem LG modules are necessary
for a-dystroglycan binding. Since agrin contains only 3 LG
modules, only one tandem is available [40]. Laminin possesses 5
LG modules which enable the formation of maximally two LG
tandems. However, their spatial relationship within the molecule
may be to close to cross link a-dystroglycan [41], for review see
[42]. The fibronectin induced rise in cytosolic calcium can in
theory be mediated via many complexes. The integrin a3b1 can
bind fibronectin via a RGD module, and is intracellulary linked to
integrin linked kinase (ILK) which is involved in regulation of the
actin cytoskeleton, morphology and cell survival via signaling
events [43,44]. However, the involvement of integrins in the
fibronectin-induced rise in cytosolic calcium was excluded by
blocking with an RGD peptide. Furthermore, probing of
podocytes with fibronectin induced a dephosphorylation of b-
dystroglycan, which makes a role for a-dystroglycan in fibronectin
induced signaling likely. Immunoprecipitation studies in our
laboratory have indeed showed that glomerular a-dystroglycan
can bind fibronectin (data not shown), confirming previously
published observations [20]. Intact fibronectin chains (,250 kDa)
can only pass the glomerular basement membrane if proteinuria is
present, and indeed urinary fibronectin correlates with proteinuria
[25–27]. Importantly, tissue fibronectin is upregulated during
several glomerular diseases [21–24].
The unraveling of the downstream signaling pathways after
dystroglycan ligation in podocytes remains challenging. The PPxY
domain of b-dystroglycan can recruit SH2/SH3 domain-contain-
ing proteins like c-Src, Fyn, Csk, NCK, SHC and Grb-2. These
interactions are enhanced by phosphorylation of pY892 [34].
From these, c-Src has been shown to be able to phosphorylate
Y892 in c-Src overexpressing COS7 cells [37]. Also the expression
of pY892 b-dystroglycan increases in COS7 cells when cultured on
coatings of laminin, agrin or fibronectin [37]. Caveolin 1 and 3 co-
express with b-dystroglycan in lipid raft domains, and bind when
Y892 is phosphorylated. Caveolin 3 has been shown to inhibit the
c-Src induced phosphorylation of Y892. [45]. Furthermore, the
proline-rich SH3 region of Grb-2 binds at the C terminal side of b-
dystroglycan [35]. p125
FAK has been shown to be linked to Grb-2,
but not directly to b-dystroglycan [46]. Taken together, the
dynamic role of b-dystroglycan in signaling seems to provide
docking sites for multiple kinases when phosphorylated, or to
provide a stable anchorage to the actin cytoskeleton when
dephosphorylated. A similar phenomenon was illustrated by a
study in which the Src family kinases were shown to be important
for the stability of dystroglycan containing clusters induced by
agrin [47]. b-dystroglycan also is able to bind ezrin, which also
affects its interaction with the actin cytoskeleton [48]. Dystrogly-
can suppresses laminin 1 and -10/11 induced ERK activation via
a6b1 integrin and direct linking of b-dystroglycan to the ERK-
MAP kinase pathway has also been described in COS 7 cells
[49,50]. Recently, genetic interaction screens on presumed
modifier genes for dystroglycan and dystrophin in many
drosophila melanogaster mutants, added even more putative
signaling pathways, like the Notch, TGF-b, EGFR, Semaphorin-
Plexin, Frazzled-Netrin and Slit-Robo pathways [51].
Unfortunately, in co-immunoprecipitation experiments we
could not find any binding of b-dystroglycan to Src, Grb2,
p125
FAK and ezrin in rat kidney lysates (data not shown). So the
signaling pathways linked to b-dystroglycan in podocytes remains
subject for further investigation.
Alterations in podocyte shape and function are calcium
dependent. This has been shown in the calcium switch model in
podocytes, in which 90 minutes removal of extracellular calcium
results in an increased paracellular flux of dextrans [52].
Mutations in the canonical transient receptor potential 6 (TRPC6)
result in an increased amplitude of the calcium current from the
extracellular calcium stores, and eventually leads to a form of
autosomal dominant focal segmental glomerulosclerosis [53,54].
However, the calcium flux induced via a-dystroglycan is derived
from the intracellular calcium stores, which suggests that TRPC6
is not involved in these events. Furthermore, podocyte shape
alterations can be induced by sialidase or puromycin aminonu-
cleoside in rats; dephosphorylation of ezrin linked to podocalyxin
via NHERF2 results in dissociation from the actin cytoskeleton
and concomitant foot process effacement [55]. The involvement of
b-dystroglycan in fibronectin-induced signaling is shown by the
decrease in phosphorylation of Y892, which however enhances
binding of the dystroglycan complex to the actin cytoskeleton via
utrophin. The impact of this enhanced binding to actin was
visualized by changes in podocyte morphology. We observed a
reorganization of the actin cytoskeleton after ligation of a-
dystroglycan, with monoclonal antibodies to a-dystroglycan and
Table 1. Percentages of podocytes with smooth, intermediate or filopodia rich surfaces after in vitro ligation with a-dystroglycan
specific antibodies, fibronectin and their respective controls.
IIH6
** TEPC 183
** VIA4.1
*** MOPC21
*** FN+ FN-
Filopodia rich
* 12 25 17 28 18 23
Intermediate
* 28 45 32 44 44 46
Smooth
* 60 30 51 28 38 30
*Smooth 0–0.2 filopodia/5 mm, intermediate 0.2–1 filopodia/5 mm or filopodia rich $1 filopodia/5 mm cell border.
**Significantly different when comparing frequencies in both columns; IIH6 vs. TEPC183 x
2=20.8, p,0.001.
***VIA4.1 vs. MOPC21 x
2=9.01, p,0.01 Fibronectin+(FN+) vs. control (FN-) x
2=1.3, p=0.25.
doi:10.1371/journal.pone.0005979.t001
Ligation of a-Dystroglycan
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by a retraction of branches of cultured mouse podocytes. Similar
observations have been made by Ru ¨diger et al. after exposure of
mouse podocytes to protamin sulfate, which resulted in instant
calcium influxes, and podocyte foot process retraction after 2 hrs
[56]. Protamin sulfate inhibits the binding of a-dystroglycan to
laminin and can also bind a-dystroglycan, in vivo injection results in
immediate foot process effacement and endocytosis of a-
dystroglycan [57]. Thus, the in vitro retraction of foot processes
may reflect in vivo podocyte foot process effacement.
In summary, the binding of fibronectin to apical free accessible
a-dystroglycan leads to signaling events in the podocytes, as
indicated by a rise in cytosolic calcium and a dephosphorylation of
b-dystroglycan, enabling utrophin and the actin cytoskeleton to
bind and retract the podocyte foot process. This may represent a
novel mechanism of podocyte foot process effacement in
proteinuric disease.
Methods
Cell culture
Conditionally immortalized mouse podocytes (MPC-5, gener-
ously provided by Peter Mundel, Division of Nephrology, Albert
Einstein College of Medicine, Bronx, NY, USA) were cultured
essentially as described before [7,38]. MPC-5 express a-dystrogly-
can at their apical and basal cell membrane [7]. Passages 12–17
were used in these experiments. Indirect immunofluorescence was
performed as described previously [7].
Anti-Mena antibody (Becton Dickinson, Transduction Labora-
tories, San Jose, CA, USA) dilution 1:40 and goat anti-mouse IgA
FITC (Southern Biotech, Birmingham, Alabama, USA) dilution
1:50 were used to probe the filopodia. [58]. Phalloidin-TRITC
(Molecular Probes, Leiden, The Netherlands) dilution 1:150, and
DAPI (Molecular Probes) dilution 3*10
25 was used to visualize the
actin cytoskeleton and DNA, respectively. Sections were investi-
gated by a Leica DM 4000 B microscope (Leica Microsystems,
Rijswijk, the Netherlands). Filopodia count on the cell border was
studied as follows: The number of filopodia of 2 mm or longer was
counted per 5 mm cell border. Cells were divided into 3 categories:
smooth 0–0.2 filopodia/5 mm, intermediate 0.2–1 filopodia/5 mm
or filopodia rich $1 filopodia/5 mm cell border. The frequencies
in the groups were compared using x
2.
For the investigation of binding, propagated podocytes were
seeded overnight on laminin EHS (Campro Scientific; Veenen-
daal, The Netherlands) or collagen A (Biochrom, Berlin,
Germany) coated 96 microwell plates (Costar, Corning Life
Sciences, Corning, NY) using 3000 podocytes/well with the
addition of 1 mM a-dystroglycan specific monoclonal antibodies,
IIH6 or VIA4.1 [59], or their respective isotype controls, MOPC
21 or TEPC 183 (Sigma, St Louis, MO). Notably, the
glycoepitopes on glomerular a-dystroglycan are recognized by
the antibodies IIH6 and VIA4.1 and expressed by cultured mouse
podocytes [7,60]. Podocytes were inversely centrifuged at 200 g
for 1 minute and carefully rinsed three times with phosphate
buffered saline (PBS, Merck, Darmstadt, Germany).
To evaluate the number of podocytes a hexosaminidase essay
was performed in which the amount of the house keeping enzyme
hexosaminidase is quantified by measuring the digestion of p-
nitrophenyl-N-acetyl-b-D-glucosamidine [61]. In short: podocytes
were incubated overnight at 37uC with 100 ml 50 mM citrate
(Merck), 3.75 mM p-nitrophenyl-N-acetyl-b-D-glucosamidine
(Sigma) and 0.25% Triton 6100 (Sigma). Thereafter, the reaction
was blocked with a solution containing 50 mM glycine (Sigma)
and 5 mM EDTA, pH 10.4, 150 ml/well. Optical density was
measured at 405 nm. Two-tailed Student-t test was performed and
P#0.05 was considered significant.
Measurement of calcium fluxes
Propagated podocytes were seeded on collagen A coated glass
cover slips and differentiated for 3 weeks. Subsequently, cells were
loaded with 5 mM fura-2-AM (Molecular Probes) and 0.025%
pluronic-F127 (Molecular Probes), added to the medium of
differentiated podocytes for 20 minutes at 37uC. Subsequently,
they were washed and mounted in a bath-chamber in 137 mM
NaCl, 3.6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5,5 mM D-
glucose and 10 mM Hepes-Tris buffer pH 7.4 (Sigma) at 37uC
and placed under an inverted microscope (Nikon) attached to a
videorate confocal microscope (Noran Instruments, Middleton,
WI). Calcium-free measurements were performed in the same
buffer without calcium and with 2 mM ethylene glycol tetra-acetic
acid (EGTA, Sigma) added. The podocytes were excited 15 times/
min at 340 and 380 nm, with an exposure time of 100 ms and
single cell emission at 492 nm was monitored as a measure of the
cytosolic free calcium concentration. Dynamic video imaging was
carried out using the MagiCal hardware and Tardis software [62].
The effects of the addition of 1 mM biglycan (Sigma), 1 mM
laminin, 1 mM IIH6, 1 mM VIA4.1, 1 mM MOPC 21, 1 mM
TEPC 183 (Sigma), 1 mM heparan sulfate (Seikagaku), a mixture
of 2 mg/ml chondroitin sulfate A, 1 mM B and C (Sigma), or
0.025 mg/ml rat fibronectin (250 kDa chains, Sigma) on calcium
fluxes were evaluated. Only for the measurement of the effect of
fibronectin on calcium fluxes, podocytes were prior to the addition
of fibronectin maintained in serum-free medium for 24 hrs.
Possible fibronectin binding sites on integrins were blocked with
GRGDS peptide (160 mM, Sigma).
Western blot analysis
Western blot analysis was performed according to the methods
of Laemmli and as described recently [10,63]. Whole podocyte cell
lysates were blotted onto nitrocellulose and blocked with 5% non-
fat dry milk (Biorad, Veenendaal, the Netherlands) in PBS.
Phosphatase inhibitors, 10 mM NaF (Sigma) and 1 mM sodium
orthovanadate (Sigma), were added to the buffers used during the
whole procedure to prevent dephosphorylation [64]. Anti-pY892
(1:50 BD Biosciences, San Jose, USA) and NCL-BDG (1:10
Novocastra, Newcastle upon Tyne, United Kingdom) were used as
primary antibodies. Peroxidase labeled goat anti mouse
IgGH+L1:5000, was used as secondary antibody.
Acknowledgments
We like to thank Kevin P. Campbell from the Howard Hughes Medical
Institute Iowa City for the generous gift of the antibodies to a-dystroglycan.
We thank Marieke Lammers, MD for technical support.
Author Contributions
Conceived and designed the experiments: NPV HJV MAHBvB JB JvdV.
Performed the experiments: NPV HJV MAHBvB JvdV. Analyzed the
data: NPV HJV MAHBvB JB JvdV. Contributed reagents/materials/
analysis tools: NPV HJV MAHBvB JB JvdV. Wrote the paper: NPV HJV
MAHBvB JB JvdV.
Ligation of a-Dystroglycan
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5979References
1. Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular
podocyte. Physiol Rev 83: 1: 253–307.
2. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW,
et al. (1992) Primary structure of dystrophin-associated glycoproteins linking
dystrophin to the extracellular matrix. Nature 355: 6362: 696–702.
3. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, et al. (1988)
Characterization of dystrophin in muscle-biopsy specimens from patients with
Duchenne’s or Becker’s muscular dystrophy. N Engl J Med 318: 21: 1363–1368.
4. Durbeej M, Larsson E, Ibraghimov-Beskrovnaya O, Roberds SL, Campbell KP,
et al. (1995) Non-muscle alpha-dystroglycan is involved in epithelial develop-
ment. J Cell Biol 130: 1: 79–91.
5. Durbeej M, Henry MD, Ferletta M, Campbell KP, Ekblom P (1998)
Distribution of dystroglycan in normal adult mouse tissues. J Histochem
Cytochem 46: 4: 449–457.
6. Raats CJ, van den Born J, Bakker MA, Oppers-Walgreen B, Pisa BJ, et al. (2000)
Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in
experimental glomerulopathies. Am J Pathol 156: 5: 1749–1765.
7. Vogtlander NPJ, Dijkman H, Bakker MAH, Campbell KP, van der Vlag J, et al.
(2005) Localization of alpha-dystroglycan on the podocyte: from top to toe.
J Histochem Cytochem 53: 11: 1345–1353.
8. Ervasti JM, Campbell KP (1993) A role for the dystrophin-glycoprotein complex
as a transmembrane linker between laminin and actin. J Cell Biol 122: 4:
809–823.
9. Regele HM, Fillipovic E, Langer B, Poczewki H, Kraxberger I, et al. (2000)
Glomerular expression of dystroglycans is reduced in minimal change nephrosis
but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 11: 3: 403–412.
10. Vogtlander NPJ, Tamboer WPM, Bakker MAH, van der Vlag J, Berden JH
(2006) Reactive oxygen species deglycosilate glomerular alpha-dystroglycan.
Kidney Int 69: 9: 1526–1534.
11. Bowe MA, Mendis DB, Fallon JR (2000) The small leucine-rich repeat
proteoglycan biglycan binds to alpha- dystroglycan and is upregulated in
dystrophic muscle. J Cell Biol 148: 4: 801–810.
12. Schaefer L, Grone HJ, Raslik I, Robenek H, Ugorcakova J, et al. (2000) Small
proteoglycans of normal adult human kidney: distinct expression patterns of
decorin, biglycan, fibromodulin, and lumican. Kidney Int 58: 4: 1557–1568.
13. Stokes MB, Holler S, Cui Y, Hudkins KL, Eitner F, et al. (2000) Expression of
decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney
Int 57: 2: 487–498.
14. Moss J, Shore I, Woodrow D (1998) An ultrastructural study of the
colocalization of biglycan and decorin with AA amyloid fibrils in human renal
glomeruli. Amyloid 5: 1: 43–48.
15. Kuroda M, Sasamura H, Kobayashi E, Shimizu-Hirota R, Nakazato Y, et al.
(2004) Glomerular expression of biglycan and decorin and urinary levels of
decorin in primary glomerular disease. Clin Nephrol 61: 1: 7–16.
16. Schaefer L, Raslik I, Grone HJ, Schonherr E, Macakova K, et al. (2001) Small
proteoglycans in human diabetic nephropathy: discrepancy between glomerular
expression and protein accumulation of decorin, biglycan, lumican, and
fibromodulin. Faseb J 15: 3: 559–561.
17. Okuda S, Languino LR, Ruoslahti E, Border WA (1990) Elevated expression of
transforming growth factor-beta and proteoglycan production in experimental
glomerulonephritis. Possible role in expansion of the mesangial extracellular
matrix. J Clin Invest 86: 2: 453–462.
18. Bjornson Granqvist A, Ebefors K, Saleem MA, Mathieson PW, Haraldsson B, et
al. (2006) Podocyte proteoglycan synthesis is involved in the development of
nephrotic syndrome. Am J Physiol Renal Physiol 291: 4: F722–730.
19. Kuroda M, Sasamura H, Shimizu-Hirota R, Mifune M, Nakaya H, et al. (2002)
Glucocorticoid regulation of proteoglycan synthesis in mesangial cells. Kidney
Int 62: 3: 780–789.
20. Hall H, Bozic D, Michel K, Hubbell JA (2003) N-terminal alpha-dystroglycan
binds to different extracellular matrix molecules expressed in regenerating
peripheral nerves in a protein-mediated manner and promotes neurite extension
of PC12 cells. Mol Cell Neurosci 24: 4: 1062–1073.
21. Kubosawa H, Kondo Y (1998) Alterations in the distribution of plasma
fibronectin and the ultrastructure of podocytes in the peripheral glomerular
loops in nephrotic rats. Virchows Arch 433: 5: 449–455.
22. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, et al. (2007) Deletion of
protein kinase C-beta isoform in vivo reduces renal hypertrophy but not
albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 56:
2: 346–354.
23. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, et al. (2007) Renoprotective
effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol
Dial Transplant 22: 2: 396–408.
24. Cohen MP, Lautenslager GT, Hud E, Shea E, Wang A, et al. (2007) Inhibiting
albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV
subchain production and the development of renal insufficiency. Am J Physiol
Renal Physiol 292: 2: F789–F795.
25. Soylemezoglu O, Wild G, Dalley AJ, MacNeil S, Milford-Ward A, et al. (1997)
Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial
Transplant 12: 9: 1883–1889.
26. Senatorski G, Paczek L, Sulowicz W, Gradowska L, Bartlomiejczyk I (1998)
Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and
fibronectin in membranous glomerulonephritis. Res Exp Med (Berl) 198: 4:
199–206.
27. Kilis-Pstrusinska K, Wikiera-Magott I, Zwolinska D, Kopec W, Rzeszutko M
(2002) Analysis of collagen IV and fibronectin in blood and urine in evaluation of
nephrotic fibrosis in children with chronic glomerulonephritis. Med Sci Monit 8:
10: CR713–CR719.
28. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP (1995) Identification
and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol
Chem 270: 45: 27305–27310.
29. Rentschler S, Linn H, Deininger K, Bedford MT, Espanel X, et al. (1999) The
WW domain of dystrophin requires EF-hands region to interact with beta-
dystroglycan. Biol Chem 380: 4: 431–442.
30. James M, Nuttall A, Ilsley JL, Ottersbach K, Tinsley JM, et al. (2000) Adhesion-
dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its interac-
tion with utrophin. J Cell Sci 113(Pt 10): 1717–1726.
31. Macias MJ, Wiesner S, Sudol M (2002) WW and SH3 domains, two different
scaffolds to recognize proline-rich ligands. FEBS Lett 513: 1: 30–37.
32. Huang X, Poy F, Zhang R, Joachimiak A, Sudol M, et al. (2000) Structure of a
WW domain containing fragment of dystrophin in complex with beta-
dystroglycan. Nat Struct Biol 7: 8: 634–638.
33. Ilsley JL, Sudol M, Winder SJ (2001) The interaction of dystrophin with beta-
dystroglycan is regulated by tyrosine phosphorylation. Cell Signal 13: 9:
625–632.
34. Sotgia F, Lee H, Bedford MT, Petrucci T, Sudol M, et al. (2001) Tyrosine
phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY,
recruits SH2 domain containing proteins. Biochemistry 40: 48: 14585–14592.
35. Yang B, Jung D, Motto D, Meyer J, Koretzky G, et al. (1995) SH3 domain-
mediated interaction of dystroglycan and Grb2. J Biol Chem 270: 20:
11711–11714.
36. Matsumura K, Chiba A, Yamada H, Fukuta-Ohi H, Fujita S, et al. (1997) A role
of dystroglycan in schwannoma cell adhesion to laminin. J Biol Chem 272: 21:
13904–13910.
37. Sotgia F, Bonuccelli G, Bedford M, Brancaccio A, Mayer U, et al. (2003)
Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular
compartment in cultured cells and skeletal muscle fibers in vivo. Biochemistry
42: 23: 7110–7123.
38. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, et al.
(1997) Rearrangements of the cytoskeleton and cell contacts induce process
formation during differentiation of conditionally immortalized mouse podocyte
cell lines. Exp Cell Res 236: 1: 248–258.
39. Berridge MJ, Bootman MD, Roderick HL (2003) Calcium signalling: dynamics,
homeostasis and remodelling. Nat Rev Mol Cell Biol 4: 7: 517–529.
40. Gesemann M, Cavalli V, Denzer AJ, Brancaccio A, Schumacher B, et al. (1996)
Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the
putative agrin receptor. Neuron 16: 4: 755–767.
41. Tisi D, Talts JF, Timpl R, Hohenester E (2000) Structure of the C-terminal
laminin G-like domain pair of the laminin alpha2 chain harbouring binding sites
for alpha-dystroglycan and heparin. Embo J 19: 7: 1432–1440.
42. Timpl R, Tisi D, Talts JF, Andac Z, Sasaki T, et al. (2000) Structure and
function of laminin LG modules. Matrix Biol 19: 4: 309–317.
43. Blattner SM, Kretzler M (2005) Integrin-linked kinase in renal disease:
connecting cell-matrix interaction to the cytoskeleton. Curr Opin Nephrol
Hypertens 14: 4: 404–410.
44. Kretzler M (2002) Regulation of adhesive interaction between podocytes and
glomerular basement membrane. Microsc Res Tech 57: 4: 247–253.
45. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, et al. (2000) Caveolin-3
directly interacts with the C-terminal tail of beta -dystroglycan. Identification of
a central WW-like domain within caveolin family members. J Biol Chem 275:
48: 38048–38058.
46. Cavaldesi M, Macchia G, Barca S, Defilippi P, Tarone G, et al. (1999)
Association of the dystroglycan complex isolated from bovine brain synapto-
somes with proteins involved in signal transduction. J Neurochem 72: 4:
1648–1655.
47. Sadasivam G, Willmann R, Lin S, Erb-Vogtli S, Kong XC, et al. (2005) Src-
family kinases stabilize the neuromuscular synapse in vivo via protein
interactions, phosphorylation, and cytoskeletal linkage of acetylcholine receptors.
J Neurosci 25: 45: 10479–10493.
48. Spence HJ, Chen YJ, Batchelor CL, Higginson JR, Suila H, et al. (2004) Ezrin-
dependent regulation of the actin cytoskeleton by beta-dystroglycan. Hum Mol
Genet 13: 15: 1657–1668.
49. Ferletta M, Kikkawa Y, Yu H, Talts JF, Durbeej M, et al. (2003) Opposing roles
of integrin alpha6-beta1 and dystroglycan in laminin-mediated extracellular
signal-regulated kinase activation. Mol Biol Cell 14: 5: 2088–20103.
50. Spence HJ, Dhillon AS, James M, Winder SJ (2004) Dystroglycan, a scaffold for
the ERK-MAP kinase cascade. EMBO Rep 5: 5: 484–489.
51. Kucherenko MM, Pantoja M, Yatsenko AS, Shcherbata HR, Fischer KA, et al.
(2008) Genetic modifier screens reveal new components that interact with the
Drosophila dystroglycan-dystrophin complex. PLoS ONE 3: 6: e2418.
52. Hunt JL, Pollak MR, Denker BM (2005) Cultured podocytes establish a size-
selective barrier regulated by specific signaling pathways and demonstrate
Ligation of a-Dystroglycan
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5979synchronized barrier assembly in a calcium switch model of junction formation.
J Am Soc Nephrol 16: 6: 1593–1602.
53. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, et al. (2005) TRPC6 is a
glomerular slit diaphragm-associated channel required for normal renal
function. Nat Genet 37: 7: 739–744.
54. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, et al. (2005) A
mutation in the TRPC6 cation channel causes familial focal segmental
glomerulosclerosis. Science 308: 5729: 1801–1804.
55. Takeda T, McQuistan T, Orlando RA, Farquhar MG (2001) Loss of glomerular
foot processes is associated with uncoupling of podocalyxin from the actin
cytoskeleton. J Clin Invest 108: 2: 289–301.
56. Rudiger F, Greger R, Nitschke R, Henger A, Mundel P, et al. (1999) Polycations
induce calcium signaling in glomerular podocytes. Kidney Int 56: 5: 1700–1709.
57. Kojima K, Davidovits A, Poczewski H, Langer B, Uchida S, et al. (2004)
Podocyte flattening and disorder of glomerular basement membrane are
associated with splitting of dystroglycan-matrix interaction. J Am Soc Nephrol
15: 8: 2079–2089.
58. Yanagida-Asanuma E, Asanuma K, Kim K, Donnelly M, Young Choi H, et al.
(2007) Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:-
Mena signaling complexes in kidney podocytes. Am J Pathol 171: 2: 415–427.
59. Ohlendieck K, Ervasti JM, Snook JB, Campbell KP (1991) Dystrophin-
glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma.
J Cell Biol 112: 1: 135–148.
60. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, et al. (2002) Post-
translational disruption of dystroglycan-ligand interactions in congenital
muscular dystrophies. Nature 418: 6896: 417–422.
61. Landegren U (1984) Measurement of cell numbers by means of the endogenous
enzyme hexosaminidase. Applications to detection of lymphokines and cell
surface antigens. J Immunol Methods 67: 2: 379–388.
62. Visch HJ, Rutter GA, Koopman WJ, Koenderink JB, Verkaart S, et al. (2004)
Inhibition of mitochondrial Na+-Ca2+ exchange restores agonist-induced ATP
production and Ca2+ handling in human complex I deficiency. J Biol Chem
279: 39: 40328–40336.
63. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227: 259: 680–685.
64. Sharma SK, Carew TJ (2002) Inclusion of phosphatase inhibitors during
Western blotting enhances signal detection with phospho-specific antibodies.
Anal Biochem 307: 1: 187–189.
65. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, et al. (2006)
Synaptopodin orchestrates actin organization and cell motility via regulation of
RhoA signalling. Nat Cell Biol 8: 5: 485–491.
Ligation of a-Dystroglycan
PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5979